Guggenheim Maintains Travere Therapeutics at Buy, Lowers Price Target to $78
Guggenheim has updated its outlook on Travere Therapeutics, maintaining a 'Buy' rating while adjusting the price target from $89 to $78.
Stocks · News reference
Travere Therapeutics Presents New Biomarker Data for FILSPARI at ASN Kidney Week 2026
Travere Therapeutics shared new Phase 3 PROTECT study data indicating that FILSPARI (sparsentan) may modify the underlying disease pathophysiology in patients with IgA nephropathy.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Travere Therapeutics Announces Participation in Upcoming Investor Conferences
Travere Therapeutics, Inc. announced that company management will participate in a series of investor conferences throughout November 2026.
Travere Therapeutics Reports Third Quarter 2026 Financial Results
Travere Therapeutics announced its financial results for the third quarter of 2026, highlighting $200 million in net product sales for FILSPARI.
Travere Therapeutics to Report Third Quarter 2026 Financial Results
Travere Therapeutics, Inc. has scheduled the release of its third quarter 2026 financial results for November 2, 2026.
FTC Says Martin Shkreli ‘Flagrantly’ Violated Lifetime Pharma Ban With Drug Stock Trades
FTC and 7 states seek contempt against Martin Shkreli, alleging he violated his lifetime pharma ban by trading biotech stocks and influencing markets.
Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $89
Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $75 to $89.